This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pérez-Trallero, E.
Right arrow Articles by Ruiz, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pérez-Trallero, E.
Right arrow Articles by Ruiz, J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2002, p. 2665-2667, Vol. 46, No. 8
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.8.2665-2667.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Activities of Six Different Quinolones against Clinical Respiratory Isolates of Streptococcus pneumoniae with Reduced Susceptibility to Ciprofloxacin in Spain

E. Pérez-Trallero,1 C. García-Rey,2 A. M. Martín-Sánchez,3 L. Aguilar,2* J. García-de-Lomas,4 J. Ruiz,5 Spanish Surveillance Group for Respiratory Pathogens (SAUCE Program) ,1,{dagger}

Microbiology Department, Hospital Donostia, San Sebastián,1 Medical Department, GlaxoSmithKline, Tres Cantos, Madrid,2 Microbiology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria,3 Instituto Valenciano de Microbiología, Valencia,4 Microbiology Department, Hospital Virgen de la Arrixaca, Murcia, Spain5

Received 8 October 2001/ Returned for modification 24 March 2002/ Accepted 13 April 2002

Six quinolones were tested on 817 consecutive pneumococcal isolates for which ciprofloxacin MICs were high (>=2 µg/ml); the isolates had been collected during two recent Spanish surveillance studies. For strains for which the ciprofloxacin MIC was >=4 µg/ml, the MICs at which 90% of the isolates tested against gemifloxacin, moxifloxacin, gatifloxacin, sparfloxacin, levofloxacin, and ofloxacin were inhibited were 0.25, 1, 1, 1, 4 and 16 µg/ml, respectively, and the corresponding prevalences of resistance were 0, 1, 4.5, 9.5, 8.4 and 23%. The proportion of isolates for which the ciprofloxacin MIC is high has increased over time.

* Corresponding author. Mailing address: Medical Department, GlaxoSmithKline, c/Doctor Severo Ochoa, 2, 28760 Tres Cantos, Madrid, Spain. Phone: 34 91 807 5912. Fax: 34 91 807 0596. E-mail: lorenzo.aguilar-alfaro{at}gsk.com.

{dagger} Members of the Spanish Surveillance Group for Respiratory Pathogens include the following (all locations are in Spain): J. Larruskain, Hospital Donostia, San Sebastián; E. Bouza and E. Cercenado, Hospital Gregorio Marañón, Madrid; J. Barrón and L. López, Hospital de Cruces, Bilbao; T. Jiménez de Anta and F. Marco, Hospital Clínico Provincial, Barcelona; E. Perea and L. Martínez, Hospital Virgen de la Macarena, Seville; C. Latorre and A. Gené, Hospital Sant Joan de Déu, Barcelona; J. A. García-Rodríguez (Study Coordinator) and I. Trujillano, Hospital Clínico Universitario, Salamanca; F. Baquero (Study Coordinator), Hospital Ramón y Cajal, Madrid; A. García, S. García, and M. Güeni, Hospital La Paz, Madrid; E. Simarro, Hospital Virgen de la Arrixaca, Murcia; C. García-Riestra, B. Regueiro, A. Jato, and M. Prieto, Hospital Clínico Universitario, Santiago de Compostela; C. Rubio and C. García, Hospital Clínico Universitario, Zaragoza; M. de la Rosa, Hospital Virgen de las Nieves, Granada; F. Cañas, Hospital Insular, Las Palmas; D. Romero and M. González, Hospital Nuestra Señora de Alarcos, Ciudad Real; J. M. Nogueira, Hospital Dr. Peset, Valencia; M. Casal and A. Ibarra, Hospital Reina Sofía, Córdoba; M. Gobernado and N. Diosdado, Hospital La Fe, Valencia; G. Prats and F. Sánchez, Hospital Santa Creu i Sant Pau, Barcelona; R. Cisterna and A. Morla, Hospital de Basurto, Bilbao; A. C. Gómez-García, and F. J. Blanco-Palenciano, Hospital Infanta Cristina, Badajoz; A. Fenoll and J. Casal, Instituto Carlos III, Madrid; J. J. Granizo, Fundación Jiménez Díaz, Madrid; L. López and C. Gimeno; Instituto Valenciano de Microbiología, Valencia; and J. E. Martín and R. Dal-Ré, GlaxoSmithKline, Tres Cantos, Madrid.

Antimicrobial Agents and Chemotherapy, August 2002, p. 2665-2667, Vol. 46, No. 8
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.8.2665-2667.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • de la Pedrosa, E. G. G., Morosini, M.-I., van der Linden, M., Ruiz-Garbajosa, P., Galan, J. C., Baquero, F., Reinert, R. R., Canton, R. (2008). Polyclonal Population Structure of Streptococcus pneumoniae Isolates in Spain Carrying mef and mef plus erm(B). Antimicrob. Agents Chemother. 52: 1964-1969 [Abstract] [Full Text]  
  • Sevillano, D., Aguilar, L., Alou, L., Gimenez, M.-J., Echevarria, O., Cafini, F., Valero, E., Fenoll, A., Prieto, J. (2006). Effects of antimicrobials on the competitive growth of Streptococcus pneumoniae: a pharmacodynamic in vitro model approach to selection of resistant populations. J Antimicrob Chemother 58: 794-801 [Abstract] [Full Text]  
  • Alou, L., Gimenez, M.-J., Sevillano, D., Aguilar, L., Cafini, F., Echeverria, O., Perez-Trallero, E., Prieto, J. (2006). A pharmacodynamic approach to antimicrobial activity in serum and epithelial lining fluid against in vivo-selected Streptococcus pneumoniae mutants and association with clinical failure in pneumonia. J Antimicrob Chemother 58: 349-358 [Abstract] [Full Text]  
  • Varon, E., Houssaye, S., Grondin, S., Gutmann, L., the Groupe des Observatoires de la Resistance du P, (2006). Nonmolecular Test for Detection of Low-Level Resistance to Fluoroquinolones in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 50: 572-579 [Abstract] [Full Text]  
  • Croisier, D., Etienne, M., Piroth, L., Bergoin, E., Lequeu, C., Portier, H., Chavanet, P. (2004). In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants. J Antimicrob Chemother 54: 640-647 [Abstract] [Full Text]  
  • Croisier, D., Etienne, M., Bergoin, E., Charles, P.-E., Lequeu, C., Piroth, L., Portier, H., Chavanet, P. (2004). Mutant Selection Window in Levofloxacin and Moxifloxacin Treatments of Experimental Pneumococcal Pneumonia in a Rabbit Model of Human Therapy. Antimicrob. Agents Chemother. 48: 1699-1707 [Abstract] [Full Text]  
  • Otani, T., Tanaka, M., Ito, E., Kurosaka, Y., Murakami, Y., Onodera, K., Akasaka, T., Sato, K. (2003). In Vitro and In Vivo Antibacterial Activities of DK-507k, a Novel Fluoroquinolone. Antimicrob. Agents Chemother. 47: 3750-3759 [Abstract] [Full Text]  
  • Morosini, M.-I., Loza, E., del Campo, R., Almaraz, F., Baquero, F., Canton, R. (2003). Fluoroquinolone-Resistant Streptococcus pneumoniae in Spain: Activities of Garenoxacin against Clinical Isolates Including Strains with Altered Topoisomerases. Antimicrob. Agents Chemother. 47: 2692-2695 [Abstract] [Full Text]  
  • Singer, M. E., Harding, I., Jacobs, M. R., Jaffe, D. H. (2003). Impact of antimicrobial resistance on health outcomes in the out-patient treatment of adult community-acquired pneumonia: a probability model. J Antimicrob Chemother 51: 1269-1282 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»